| Line 718: | Line 718: | ||
===2021: | ===2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981929/ Reducing the smoking-related health burden in the USA through diversion to electronic cigarettes: a system dynamics simulation study]=== | ||
*The simulation suggests that the promotion of e-cigarettes as a harm-reduction policy is a viable strategy, given current evidence that e-cigarettes offset or divert from smoking. Given the strong effects of implementation challenges on policy effectiveness in the short term, accurately modeling such obstacles can usefully inform policy design. | *The simulation suggests that the promotion of e-cigarettes as a harm-reduction policy is a viable strategy, given current evidence that e-cigarettes offset or divert from smoking. Given the strong effects of implementation challenges on policy effectiveness in the short term, accurately modeling such obstacles can usefully inform policy design. | ||
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981929/pdf/12954_2021_Article_484.pdf PDF Version] | *[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981929/pdf/12954_2021_Article_484.pdf PDF Version] | ||
*Citation: Selya AS. Reducing the smoking-related health burden in the USA through diversion to electronic cigarettes: a system dynamics simulation study. Harm Reduct J. 2021;18(1):36. Published 2021 Mar 20. doi:10.1186/s12954-021-00484-6 | *Citation: Selya AS. Reducing the smoking-related health burden in the USA through diversion to electronic cigarettes: a system dynamics simulation study. Harm Reduct J. 2021;18(1):36. Published 2021 Mar 20. doi:10.1186/s12954-021-00484-6 | ||
*Acknowledgement: This work was supported by the National Institute for General Medical Sciences (NIGMS) within the National Institutes of Health (NIH), grant number P20GM121341; by the Norwegian Agency for International Cooperation and Quality Enhancement in Higher Education (DIKU), grant number NNA-2016/10023. After the initial submission of this manuscript, AS became employed by Pinney Associates, Inc. which provides consulting services on tobacco harm minimization to JUUL Labs, Inc. The content presented here precedes this competing interest, and JUUL Labs, Inc. and PinneyAssociates, Inc. had any role in the conceptualization, design, analysis, interpretation, or presentation of data, nor in the decision to publish. | *Acknowledgement: This work was supported by the National Institute for General Medical Sciences (NIGMS) within the National Institutes of Health (NIH), grant number P20GM121341; by the Norwegian Agency for International Cooperation and Quality Enhancement in Higher Education (DIKU), grant number NNA-2016/10023. After the initial submission of this manuscript, AS became employed by Pinney Associates, Inc. which provides consulting services on tobacco harm minimization to JUUL Labs, Inc. The content presented here precedes this competing interest, and JUUL Labs, Inc. and PinneyAssociates, Inc. had any role in the conceptualization, design, analysis, interpretation, or presentation of data, nor in the decision to publish. | ||
===2020: [https://pubmed.ncbi.nlm.nih.gov/32770246/ QuitNic: A pilot randomised controlled trial comparing nicotine vaping products with nicotine replacement therapy for smoking cessation following residential detoxification]=== | ===2020: [https://pubmed.ncbi.nlm.nih.gov/32770246/ QuitNic: A pilot randomised controlled trial comparing nicotine vaping products with nicotine replacement therapy for smoking cessation following residential detoxification]=== | ||
edits